Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis

American Journal of Kidney Diseases

Volumn 49, Issue 2, 2007, Pages 186-193

  Zhu, Xiaolei ^a   Wu, Shenhong ^a   Dahut, William L ^a   Parikh, Chirag R ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

anti VEGF antibody; Bevacizumab; cancer; hypertension; proteinuria; vascular endothelial growth factor (VEGF)

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN ANTIBODY;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; PATHOGENESIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SYSTEMATIC REVIEW; URINALYSIS;

ANTIBODIES, MONOCLONAL; HUMANS; HYPERTENSION; PROTEINURIA; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846638744     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.11.039     Document Type: Article

References (29)

1. Hurwitz H., Fehrenbacher L., and Novotny W. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
2. Hurwitz H.I., Fehrenbacher L., Hainsworth J.D., et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23 (2005) 3502-3508
3. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 (2005) 792-799
4. Sandler AB, Gray R, Brahmer J, et al: Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005 (abstr 4)
5. de Gramont A., and Van Cutsem E. Investigating the potential of bevacizumab in other indications: Metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 69 suppl 3 (2005) S46-S56
6. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
7. Lau J., Ioannidis J.P., and Schmid C.H. Quantitative synthesis in systematic reviews. Ann Intern Med 127 (1997) 820-826
8. Zhou X.H., Brizendine E.J., and Pritz M.B. Methods for combining rates from several studies. Stat Med 18 (1999) 557-566
9. Johnson D.H., Fehrenbacher L., and Novotny W.F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22 (2004) 2184-2191
10. Kabbinavar F., Hurwitz H.I., and Fehrenbacher L. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
11. Kabbinavar F.F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23 (2005) 3697-3705
12. Kindler HL, Karrison T, Gandara DR, et al: A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). Presented at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL, May 13-17, 2005 (abstr 7019)
13. Kabbinavar F.F., Hambleton J., Mass R.D., et al. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23 (2005) 3706-3712
14. Kaplan N.M., and Opie L.H. Controversies in hypertension. Lancet 367 (2006) 168-176
15. Peterson J.C., Adler S., Burkart J.M., et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123 (1995) 754-762
16. Wachtell K., Ibsen H., Olsen M.H., et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 139 (2003) 901-906
17. Weisstuch J.M., and Dworkin L.D. Does essential hypertension cause end-stage renal disease?. Kidney Int Suppl 36 (1992) S33-S37
18. Siddiqui A.J., Mansson-Broberg A., Gustafsson T., et al. Antagonism of the renin-angiotensin system can counteract cardiac angiogenic vascular endothelial growth factor gene therapy and myocardial angiogenesis in the normal heart. Am J Hypertens 18 (2005) 1347-1352
19. Gordon M.S., and Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 69 suppl 3 (2005) S25-S33
20. Paude A.U., Lombardo J.C., Fakih M., et al. Bevacizumab (BV) induced hypertension (HT): A manageable toxicity. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24 18S (2006) (June 20 suppl) 2006: 13539
21. Genentech: Avastin labeling text, FDA Approval Date: September 2005. Available at: http://www.fda.gov/medwatch/SAFETY/2005/Jan_PI/Avastin_PI.pdf. Accessed December 21, 2006
22. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25 (2004) 581-611
23. Rini B.I., Sosman J.A., and Motzer R.J. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: Biology, clinical results and future development. BJU Int 96 (2005) 286-290
24. Vuorela P., Helske S., Hornig C., et al. Amniotic fluid-Soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol 95 (2000) 353-357
25. Kincaid-Smith P. The renal lesion of preeclampsia revisited. Am J Kidney Dis 17 (1991) 144-148
26. Eremina V., Sood M., Haigh J., et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111 (2003) 707-716
27. Neagoe P.E., Lemieux C., and Sirois M.G. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem 280 (2005) 9904-9912
28. Yang R., Thomas G.R., Bunting S., et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 27 (1996) 838-844
29. Henry T.D., Annex B.H., McKendall G.R., et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107 (2003) 1359-1365